Natixis Purchases 3,461,074 Shares of Pfizer Inc. (NYSE:PFE)

Natixis lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 190.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,276,396 shares of the biopharmaceutical company's stock after purchasing an additional 3,461,074 shares during the period. Pfizer accounts for about 0.9% of Natixis' investment portfolio, making the stock its 18th biggest holding. Natixis owned about 0.09% of Pfizer worth $139,983,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of PFE. PSI Advisors LLC lifted its position in shares of Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its position in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after buying an additional 391 shares during the last quarter. D Orazio & Associates Inc. increased its position in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its position in shares of Pfizer by 2.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after buying an additional 401 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.12 during midday trading on Wednesday, reaching $22.41. The company's stock had a trading volume of 32,999,021 shares, compared to its average volume of 40,427,391. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $127.10 billion, a P/E ratio of 15.89, a PEG ratio of 0.64 and a beta of 0.67. The firm has a 50 day moving average price of $24.75 and a 200-day moving average price of $26.08. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. UBS Group reduced their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday. They issued a "neutral" rating and a $24.00 price objective for the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.